Novel approaches in melanoma prevention and therapy

Antonio M. Grimaldi, Pamela Cassidy, Sancy Leachmann, Paolo A. Ascierto

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

The incidence of cutaneous melanoma has risen at a rate significantly higher than that for other malignancies. This increase persists despite efforts to educate the public about the dangers of excess exposure to UV radiation from both the sun and tanning beds. Melanoma affects a relatively younger population and is notorious for its propensity to metastasize and for its poor response to current therapeutic regimens. These factors make prevention an integral component to the goal of decreasing melanoma-related mortality. Transformation of melanocytes into malignant melanoma involves the interplay between genetic factors, UV exposure, and the tumor microenvironment. The roles of UV radiation in the etiology of melanoma are mediated by both direct damage of DNA through formation of photoproducts and production of reactive oxygen species (ROS). Many of the promising antioxidant agents under development for the prevention of melanoma are derived from foodstuffs. B-Raf is a member of the Raf kinase family of serine/threonine-specific protein kinases that plays a role in regulating the MAP kinase/ERKs signaling pathway. About 50% of melanomas harbor activating BRAF mutations. BRAF mutations are found in 59% of the melanomas arising in skin with intermittent sun exposure, such as trunk and arms, as compared with only 23% of the acral melanomas, 11% of mucosal melanomas, and 0% of uveal melanomas. Two new agents, ipilimumab and vemurafenib, have been shown to improve outcome of advanced melanoma as presented at the plenary session of the 2011 annual meeting of the American Society of Clinical Oncology. Vemurafenib is the first personalized compound which demonstrated an improvement in progressionfree survival (PFS) and overall survival (OS) in metastatic melanoma harbouring the BRAFV600 mutation and represents the first drug of a class that exerts its anti-proliferative activity through inhibition of a highly specific molecular target. GSK2118436 (dabrafenib), the second BRAF inhibitor, in phase I and II trial obtained similar results to vemurafenib. A phase III trial is now ongoing. Taken together, the early clinical development of vemurafenib and dabrafenib clearly confirms that BRAF inhibitors can halt or reverse disease in patients with melanomas carrying this mutation, improving survival times compared with historically standard treatments (chemotherapy and interleukin-2). The clinical development of other new BRAF inhibitors such as RAF265 and LGX818 is now ongoing. Combination strategies of BRAF inhibitors with ipilimumab, an anti-CTLA-4 antibody, and/or MEK inhibitors or metformin are now under investigation in clinical trials.

Original languageEnglish (US)
Pages (from-to)443-455
Number of pages13
JournalCancer Treatment and Research
Volume159
DOIs
StatePublished - 2014
Externally publishedYes

Fingerprint

Melanoma
Therapeutics
Mutation
MAP Kinase Signaling System
Solar System
Survival
raf Kinases
Radiation
Tanning
Skin
Tumor Microenvironment
Metformin
Protein-Serine-Threonine Kinases
Melanocytes
Mitogen-Activated Protein Kinase Kinases
DNA Damage
Interleukin-2
Reactive Oxygen Species
Extremities
Antioxidants

Keywords

  • BRAF
  • Dabrafenib
  • Ipilimumab
  • Melanoma
  • Vemurafenib

ASJC Scopus subject areas

  • Oncology
  • Cancer Research
  • Medicine(all)

Cite this

Novel approaches in melanoma prevention and therapy. / Grimaldi, Antonio M.; Cassidy, Pamela; Leachmann, Sancy; Ascierto, Paolo A.

In: Cancer Treatment and Research, Vol. 159, 2014, p. 443-455.

Research output: Contribution to journalArticle

Grimaldi, Antonio M. ; Cassidy, Pamela ; Leachmann, Sancy ; Ascierto, Paolo A. / Novel approaches in melanoma prevention and therapy. In: Cancer Treatment and Research. 2014 ; Vol. 159. pp. 443-455.
@article{209e2e8ed489493f8a8b9c68ff3b64f1,
title = "Novel approaches in melanoma prevention and therapy",
abstract = "The incidence of cutaneous melanoma has risen at a rate significantly higher than that for other malignancies. This increase persists despite efforts to educate the public about the dangers of excess exposure to UV radiation from both the sun and tanning beds. Melanoma affects a relatively younger population and is notorious for its propensity to metastasize and for its poor response to current therapeutic regimens. These factors make prevention an integral component to the goal of decreasing melanoma-related mortality. Transformation of melanocytes into malignant melanoma involves the interplay between genetic factors, UV exposure, and the tumor microenvironment. The roles of UV radiation in the etiology of melanoma are mediated by both direct damage of DNA through formation of photoproducts and production of reactive oxygen species (ROS). Many of the promising antioxidant agents under development for the prevention of melanoma are derived from foodstuffs. B-Raf is a member of the Raf kinase family of serine/threonine-specific protein kinases that plays a role in regulating the MAP kinase/ERKs signaling pathway. About 50{\%} of melanomas harbor activating BRAF mutations. BRAF mutations are found in 59{\%} of the melanomas arising in skin with intermittent sun exposure, such as trunk and arms, as compared with only 23{\%} of the acral melanomas, 11{\%} of mucosal melanomas, and 0{\%} of uveal melanomas. Two new agents, ipilimumab and vemurafenib, have been shown to improve outcome of advanced melanoma as presented at the plenary session of the 2011 annual meeting of the American Society of Clinical Oncology. Vemurafenib is the first personalized compound which demonstrated an improvement in progressionfree survival (PFS) and overall survival (OS) in metastatic melanoma harbouring the BRAFV600 mutation and represents the first drug of a class that exerts its anti-proliferative activity through inhibition of a highly specific molecular target. GSK2118436 (dabrafenib), the second BRAF inhibitor, in phase I and II trial obtained similar results to vemurafenib. A phase III trial is now ongoing. Taken together, the early clinical development of vemurafenib and dabrafenib clearly confirms that BRAF inhibitors can halt or reverse disease in patients with melanomas carrying this mutation, improving survival times compared with historically standard treatments (chemotherapy and interleukin-2). The clinical development of other new BRAF inhibitors such as RAF265 and LGX818 is now ongoing. Combination strategies of BRAF inhibitors with ipilimumab, an anti-CTLA-4 antibody, and/or MEK inhibitors or metformin are now under investigation in clinical trials.",
keywords = "BRAF, Dabrafenib, Ipilimumab, Melanoma, Vemurafenib",
author = "Grimaldi, {Antonio M.} and Pamela Cassidy and Sancy Leachmann and Ascierto, {Paolo A.}",
year = "2014",
doi = "10.1007/978-3-642-38007-5_25",
language = "English (US)",
volume = "159",
pages = "443--455",
journal = "Cancer Treatment and Research",
issn = "0927-3042",
publisher = "Springer Netherlands",

}

TY - JOUR

T1 - Novel approaches in melanoma prevention and therapy

AU - Grimaldi, Antonio M.

AU - Cassidy, Pamela

AU - Leachmann, Sancy

AU - Ascierto, Paolo A.

PY - 2014

Y1 - 2014

N2 - The incidence of cutaneous melanoma has risen at a rate significantly higher than that for other malignancies. This increase persists despite efforts to educate the public about the dangers of excess exposure to UV radiation from both the sun and tanning beds. Melanoma affects a relatively younger population and is notorious for its propensity to metastasize and for its poor response to current therapeutic regimens. These factors make prevention an integral component to the goal of decreasing melanoma-related mortality. Transformation of melanocytes into malignant melanoma involves the interplay between genetic factors, UV exposure, and the tumor microenvironment. The roles of UV radiation in the etiology of melanoma are mediated by both direct damage of DNA through formation of photoproducts and production of reactive oxygen species (ROS). Many of the promising antioxidant agents under development for the prevention of melanoma are derived from foodstuffs. B-Raf is a member of the Raf kinase family of serine/threonine-specific protein kinases that plays a role in regulating the MAP kinase/ERKs signaling pathway. About 50% of melanomas harbor activating BRAF mutations. BRAF mutations are found in 59% of the melanomas arising in skin with intermittent sun exposure, such as trunk and arms, as compared with only 23% of the acral melanomas, 11% of mucosal melanomas, and 0% of uveal melanomas. Two new agents, ipilimumab and vemurafenib, have been shown to improve outcome of advanced melanoma as presented at the plenary session of the 2011 annual meeting of the American Society of Clinical Oncology. Vemurafenib is the first personalized compound which demonstrated an improvement in progressionfree survival (PFS) and overall survival (OS) in metastatic melanoma harbouring the BRAFV600 mutation and represents the first drug of a class that exerts its anti-proliferative activity through inhibition of a highly specific molecular target. GSK2118436 (dabrafenib), the second BRAF inhibitor, in phase I and II trial obtained similar results to vemurafenib. A phase III trial is now ongoing. Taken together, the early clinical development of vemurafenib and dabrafenib clearly confirms that BRAF inhibitors can halt or reverse disease in patients with melanomas carrying this mutation, improving survival times compared with historically standard treatments (chemotherapy and interleukin-2). The clinical development of other new BRAF inhibitors such as RAF265 and LGX818 is now ongoing. Combination strategies of BRAF inhibitors with ipilimumab, an anti-CTLA-4 antibody, and/or MEK inhibitors or metformin are now under investigation in clinical trials.

AB - The incidence of cutaneous melanoma has risen at a rate significantly higher than that for other malignancies. This increase persists despite efforts to educate the public about the dangers of excess exposure to UV radiation from both the sun and tanning beds. Melanoma affects a relatively younger population and is notorious for its propensity to metastasize and for its poor response to current therapeutic regimens. These factors make prevention an integral component to the goal of decreasing melanoma-related mortality. Transformation of melanocytes into malignant melanoma involves the interplay between genetic factors, UV exposure, and the tumor microenvironment. The roles of UV radiation in the etiology of melanoma are mediated by both direct damage of DNA through formation of photoproducts and production of reactive oxygen species (ROS). Many of the promising antioxidant agents under development for the prevention of melanoma are derived from foodstuffs. B-Raf is a member of the Raf kinase family of serine/threonine-specific protein kinases that plays a role in regulating the MAP kinase/ERKs signaling pathway. About 50% of melanomas harbor activating BRAF mutations. BRAF mutations are found in 59% of the melanomas arising in skin with intermittent sun exposure, such as trunk and arms, as compared with only 23% of the acral melanomas, 11% of mucosal melanomas, and 0% of uveal melanomas. Two new agents, ipilimumab and vemurafenib, have been shown to improve outcome of advanced melanoma as presented at the plenary session of the 2011 annual meeting of the American Society of Clinical Oncology. Vemurafenib is the first personalized compound which demonstrated an improvement in progressionfree survival (PFS) and overall survival (OS) in metastatic melanoma harbouring the BRAFV600 mutation and represents the first drug of a class that exerts its anti-proliferative activity through inhibition of a highly specific molecular target. GSK2118436 (dabrafenib), the second BRAF inhibitor, in phase I and II trial obtained similar results to vemurafenib. A phase III trial is now ongoing. Taken together, the early clinical development of vemurafenib and dabrafenib clearly confirms that BRAF inhibitors can halt or reverse disease in patients with melanomas carrying this mutation, improving survival times compared with historically standard treatments (chemotherapy and interleukin-2). The clinical development of other new BRAF inhibitors such as RAF265 and LGX818 is now ongoing. Combination strategies of BRAF inhibitors with ipilimumab, an anti-CTLA-4 antibody, and/or MEK inhibitors or metformin are now under investigation in clinical trials.

KW - BRAF

KW - Dabrafenib

KW - Ipilimumab

KW - Melanoma

KW - Vemurafenib

UR - http://www.scopus.com/inward/record.url?scp=84896117104&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84896117104&partnerID=8YFLogxK

U2 - 10.1007/978-3-642-38007-5_25

DO - 10.1007/978-3-642-38007-5_25

M3 - Article

C2 - 24114495

AN - SCOPUS:84896117104

VL - 159

SP - 443

EP - 455

JO - Cancer Treatment and Research

JF - Cancer Treatment and Research

SN - 0927-3042

ER -